We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Working…

ClinicalTrials.gov Menu

WIRE - Novel Treatments in Renal Cell Cancer (WIRE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03741426

Recruitment Status : Recruiting

First Posted : November 14, 2018

Last Update Posted : May 25, 2021

See Contacts and Locations

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

University of Cambridge

AstraZeneca

Cancer Research UK

Information provided by (Responsible Party):

CCTU- Cancer Theme, Cambridge University Hospitals NHS Foundation Trust

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	April 25, 2022
Estimated Study Completion Date :	April 25, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ursprung S, Mossop H, Gallagher FA, Sala E, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. BMC Cancer. 2021 Nov 18;21(1):1238. doi: 10.1186/s12885-021-08965-4.